Utilidad de la procalcitonina en pacientes hospitalizados con infecciones virales o bacterianas ¿predice inicio o suspensión del antibiótico?

Resumen

Metodología: Se realizó una revisión sistemática a través de diversas bases de datos de enero de 2011 a febrero de 2022; la búsqueda y selección de artículos fue llevada a cabo en revistas indexadas en idioma inglés. Se utilizaron como palabras clave: Procalcitonina; infecciones; Sepsis; Bacterias; Virus. Resultados: En la actualidad existen diferentes tipos de marcadores inflamatorios, dentro de las cuales podemos destacar a la procalcitonina, que se ha convertido en un nuevo biomarcador para la detección temprana de infecciones bacterianas, especialmente las infecciones sistémicas. La fuente principal de la procalcitonina se encuentra a nivel tiroideo. Después de una infección bacteriana inicial, se ha demostrados que los niveles de procalcitonina aumentan de 6 a 12 horas, y estos valores siguen aumentando constantemente de 2 a 4 horas después del inicio de la sepsis. Después de identificar la afección, es recomendable hacer una medición de la procalcitonina cada 6 a 24 horas, con el fin de identificar la necesidad de cambiar el antibiótico. Conclusiones: La presente revisión ofrece información actualizada y detallada sobre la importancia de la procalcitonina como agente discriminatorio de enfermedades virales de las bacterianas y a así la suspensión o no del antibiótico.

Palabras clave: procalcitonina, infecciones, sepsis, bacterias, virus

Descargas

La descarga de datos todavía no está disponible.

Citas

Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol. 2011 Feb;135(2):182-9.

Lippi G, Sanchis-Gomar F. Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. World J Gastroenterol. 2017 Dec 21;23(47):8283-8290.

Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011 Sep 22;9:107.

Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis. 2014 Dec 15;59(12):1761-7.

Salinas M, López-Garrigós M, Flores E, Uris J, Leiva-Salinas C., Pilot Group of the Appropriate Utilization of Laboratory Tests (REDCONLAB) working group. Procalcitonin in the Emergency Department: A potential expensive over-request that can be modulated through institutional protocols. Am J Emerg Med. 2018 Jan;36(1):158-160.

Kip MMA, van Oers JA, Shajiei A, Beishuizen A, Berghuis AMS, Girbes AR, de Jong E, de Lange DW, Nijsten MWN, IJzerman MJ, Koffijberg H, Kusters R. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands. Crit Care. 2018 Nov 13;22(1):293

Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017 Mar;49(3)

Koropatkin NM, Cameron EA, Martens EC. 2012. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 10: 323–335.

Lu Q, Li S, Shao F. 2015. Sweet talk: Protein glycosylation in bacterial interaction with the host. Trends Microbiol 23: 630–641.

Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, Lee PS, Razi N, Wilson IA, Woods RJ, Paulson JC. 2017. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe 21: 23–34

Zingg W. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infect. Dis. 2017;17:381–389.

van Houten C.B. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect. Dis. 2017;17:431–440.

Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583-92. 10.1515/cclm-2014-1015

Kondo Y, Umemura Y, Hayashida K, et al. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care 2019;7:22. 10.1186/s40560-019-0374-4

van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicenter non-inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018;24:1282-89. 10.1016/j.cmi.2018.05.011

Peng F, Chang W, Xie JF, et al. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: a meta-analysis. Int J Infect Dis 2019;85:158-66. 10.1016/j.ijid.2019.05.034

Jeon K, Suh JK, Jang EJ, et al. Procalcitonin-guided treatment on duration of antibiotic therapy and cost in septic patients (PRODA): a multi-center randomized controlled trial. J Korean Med Sci 2019;34:e110. 10.3346/jkms.2019.34.e110

Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014;190:1102-10. 10.1164/rccm.201408-1483OC

Iankova I, Thompson-Leduc P, Kirson NY, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis. Crit Care Med 2018;46:691-8. 10.1097/CCM.0000000000002928

Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care 2018;22:191. 10.1186/s13054-018-2125-7

de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. Lancet Infect Dis 2016;16:819-27. 10.1016/S1473-3099(16)00053-0

Bréchot N, Hekimian G, Chastre J, et al. Procalcitonin to guide antibiotic therapy in ICU. Int J Antimicrob Agents 2015;46:S19-24. 10.1016/j.ijantimicag.2015.10.012

Albrich WC, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med 2015;41:1739-51. 10.1007/s00134-015-3978-8

Pieralli F, Corbo L, Torrigiani A, et al. Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit. Intern Emerg Med 2017;12:629-35. 10.1007/s11739-017-1627-7

Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults. Chest 2019;155:1109-18. 10.1016/j.chest.2018.12.029

Kip MMA, Kusters R, Ijzerman MJ, et al. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ 2015;18:944-53. 10.3111/13696998.2015.1064934

Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017;(10):CD007498

Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018;379:236-49. 10.1056/NEJMoa1802670

Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2020;70:538-42.

Pantzaris ND, Spilioti DX, Psaromyalou A, et al. The use of serum procalcitonin as a diagnostic and prognostic biomarker in chronic obstructive pulmonary disease exacerbations: a literature review update. J Clin Med Res 2018;10:545-51. 10.14740/jocmr3458w

Joshua, V. Maithili, R. Joseph, B. Gavin, Procalcitonin to Guide Antibiotic Therapy for Respiratory Infection: A Systematic Review of Systematic Reviews. Open Forum Infect Dis. 2020 Oct; 7(Suppl 1): S73. doi: 10.1093/ofid/ofaa439.164

A. Maria, R. Marco, P. Sette, A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. Ann Transl Med. 2020 May; 8(9): 610. doi: 10.21037/atm-20-1855

Publicado
2022-06-20
Cómo citar
Llerena Velasteguí, J. G., Medina Medina, L. M., Torres Hernández, F. A., Caicedo Sánchez, D. C., Rojas Avila, C. J., Rincón Mayorga, A. F., Neuta Gil, L. I., Cárdenas Trujillo, Y. C., & Julio Patiño, W. G. (2022). Utilidad de la procalcitonina en pacientes hospitalizados con infecciones virales o bacterianas ¿predice inicio o suspensión del antibiótico?. Ciencia Latina Revista Científica Multidisciplinar, 6(3), 2441-2454. https://doi.org/10.37811/cl_rcm.v6i3.2388
Sección
Artículos